Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2169 studies found for:    "cytogenetically normal acute myeloid leukemia" OR "Leukemia, Myeloid, Acute"
Show Display Options
Rank Status Study
21 Recruiting Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: Idarubicin
22 Active, not recruiting Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: decitabine iv;   Drug: volasertib iv infusion
23 Completed Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: Cytosar;   Drug: Arsenic trioxide
24 Completed A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission
Condition: Leukemia, Myeloid, Acute
Intervention: Biological: CSL362
25 Recruiting A Study to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: Decitabine;   Drug: BI 836858
26 Active, not recruiting Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: BI 6727 (d1 and 15);   Drug: Cytarabine
27 Recruiting BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: BI 836858
28 Unknown  Phase I Trial to Investigate Cafusertib Hydrochloride in Combination With Low Dose Cytarabine in Chinese Patients With Acute Myeloid Leukaemia (AML)
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: Cafusertib Hydrochloride
29 Recruiting A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: Cobimetinib;   Drug: Idasanutlin;   Drug: Venetoclax
30 Recruiting A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Interventions: Biological: PNK-007;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Human recombinant Interleukin-2 (rhIL-2)
31 Active, not recruiting Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: placebo;   Drug: volasertib;   Drug: low dose cytarabine
32 Not yet recruiting A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: Volasertib
33 Completed BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: BI 2536
34 Recruiting PreventiOn of DYSbioSis Complications With Autologous Fecal Microbiota Transplantation in acutE myEloid Leukemia Patients Undergoing Intensive Treatment
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: Autologous Fecal Microbiota Transplantation
35 Completed Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years
Condition: Acute Myeloblastic Leukaemia
Interventions: Drug: ARA-C;   Drug: Idarubicin;   Drug: Leucomax
36 Suspended Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Condition: Leukemia, Myeloid, Acute
Intervention: Drug: JNJ-63709178
37 Recruiting Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: Azacitadine;   Drug: Fludarabine;   Drug: Cytarabine;   Drug: Lenograstim;   Drug: Filgastrim
38 Unknown  Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients
Condition: Acute Myeloid Leukemia
Intervention: Drug: Idarubicin
39 Recruiting Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Relapsed Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
Intervention: Drug: cabozantinib
40 Unknown  Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Intervention: Drug: CHR-2797

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.